Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services symbols : Ganx save search
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
Published: 2024-04-08 (Crawled : 13:30) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 0.28%
H: 0.0%
C: -3.92%
management therapeutics financial
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
Published: 2024-04-01 (Crawled : 14:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 6.1%
H: 0.0%
C: -4.25%
management medical therapeutics
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 8.45%
C: 4.11%
year update therapeutics financial results
Gain Therapeutics to Present at Public Ventures Discovery Day
Published: 2024-03-15 (Crawled : 19:00) - globenewswire.com
MDBH | $9.11 2.42% 2.36% 13K
|
| Email alert
Add to watchlist
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
day therapeutics
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -4.66%
H: 6.67%
C: 3.56%
gt-0228 conference disease treatment parkinson’s therapeutics
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Published: 2024-02-14 (Crawled : 18:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 5.32%
C: 4.88%
disease update parkinson’s therapeutics
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 15:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease update parkinson’s
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease parkinson’s
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 2.33%
H: 0.76%
C: -2.27%
ceo update
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Published: 2024-01-02 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 1.07%
H: 29.62%
C: 9.85%
presentation therapeutics platform
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
Published: 2023-12-04 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 8.18%
H: 0.42%
C: -1.26%
research family therapeutics
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 5.61%
C: 2.8%
preclinical therapeutics
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 2.07%
H: 5.19%
C: 0.68%
drug therapeutics
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
Published: 2023-11-24 (Crawled : 18:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
offering therapeutics
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
Published: 2023-11-21 (Crawled : 14:30) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -20.96%
H: 2.33%
C: -3.72%
offering therapeutics
Gain Therapeutics Announces Proposed Public Offering
Published: 2023-11-20 (Crawled : 21:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -20.96%
H: 2.33%
C: -3.72%
offering therapeutics
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 2.87%
H: 0.0%
C: -3.14%
business update therapeutics financial results
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -2.06%
H: 2.8%
C: -4.65%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 0.0%
C: -1.54%
conference global therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.